S c i e n t i f i c Ι C u l t u r a l E v e n t s & P u b l i c a t i o n s Τ 210 7240039 F 210 7240139 E info@scep.gr www.scep.gr

h t t p : / / h e l l e n i c - i m m u n o o n c o l o g y . g r / Organized by Hellenic Society of Immuno-Oncology

November 29 - December 1 . 2018 Royal Olympic Hotel Athens | Greece

Symposium on Advances in

Cancer Immunology andImmunotherapy

S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y

03

Thursday, November 29th, 201814:45-15:00 Welcome

SESSION 1: Overcoming immune suppression15:00-15:30 The role of Myeloid-derived suppressor cells in tumor immune evasion V. Bronte (IT) 15:30-16:00 Immune suppression in Melanoma V. Umansky (GE) 16:00-16:30 Interplay between cellular senescence and cancer D. Kletsas (GR)

Plenary lecture16:30-17:15 Tregs T. Whiteside (USA)

17:15-17:45 Co f fee Break

SESSION 2: The role of innate immunity in cancer

17:45-18:15 The regulatory role of chemokines in cancer progression N. Karin (IL) 18:15-18:45 Toll-like receptors T. Bagratuni (GR) 18:45-19:15 Regulation of tumor metastases by NK cells O. Mandelboim (GE)

Plenary lecture

19:15-20:00 Cancer Stem Cells In breast carcinomas F. Cavallo (IT)

20:00 Welcome reception

Friday, November 30th, 2018 SESSION 3: Monitoring of immunomodulatory mechanisms09:30-10:00 The emerging role of exosomes T.L. Whiteside (USA) 10:00-10:30 Proteomics-proteogenomics T. Katsila (GR) 10:30-11:00 Lipid metabolism and anticancer immunity G. Adema (NL) 11:00-11:30 TBA P. Verginis (GR)

Plenary lecture11:30-12:15 The immunomodulatory role of microRNAs during the process of tumor immune evasion B. Seliger (GE)

12:15-12:45 Co f fee b reak

12:45-14:30 Short oral presentations-research

14:30-15:30 Lunch

SESSION 4: Special session on combinational treatment (I) 15:30-16:00 Targetingstrategiestoenhancetheeffectivenessofimmunotherapies Ed. C. Lavelle (IE) 16:00-16:30 Interplay of radiation and immunotherapy TBA 16:30-17:00 Combination of anti-PD1/PDL1 with newer immunomodulatory agents (newer ICI, IDO, TGF-b CD40 agonists, IL-15...) TBA 17:00-17:30 Immune checkpoint inhibitors and chemotherapy: update of the recently published studies TBD

17:30-18:00 Co f fee b reak

Dear Colleagues,

The Hellenic Society of Immuno-Oncology organizes the 4th Symposium on Advances in Cancer Immunology and

Immunotherapy, which will be held on November 29 - December 1, 2018, in Athens, Greece.

The meeting aim to bring together many of the leading researchers and clinicians in Europe and the US to report on

most recent advances made in cancer immunology and immunotherapy. Our main objectives are to gather, share

and exchange experiences and ideas; translate and extend this knowledge to the clinic; promote interactions between

speakers and participants and encourage stimulating discussions; provide network opportunities and stimulate new

collaborations. This year, we have introduced a new element, as all young researchers that will participate in the poster

sessions will be additionally given the opportunity to present the highlights of their work as a short oral presentation

(5 - 10 minutes each).

OnbehalfoftheOrganizingandScientificCommittees,wearepleasedtoinviteyoutoparticipate.Wehopethatyouwill

share this event within your community and invite your colleagues and students to take part as well.

WeverymuchlookforwardseeingyouthisNovemberinAthens.

Best regards,

The Organizing Committee Chairs

Athanasios Kotsakis, MD, PhD,

Associate Professor of Medical Oncology,

Director of Dpt of Medical Oncology,

University Hospital of Larisa,

Thessaly, Greece

Ourania Tsitsilonis, MD, PhD,

Associate Professor of Immunology,

Department of Biology,

National & Kapodistrian

University of Athens, Greece

Nikolaos Kentepozidis, MD, PhD,

Medical Oncologist,

Head of Oncology Clinic,

251 General Airforce Hospital,

Athens, Greece

Constantin N. Baxevanis, PhD,

ScientificDirector,

Cancer Immunology and

Immunotherapy Center “Agios Savvas”

Hospital, Athens, Greece

S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y

04 05

SESSION 5: Special session on combinational treatment (II)18:00-18:30 ICI and targeted therapies N. Karachaliou (ES) 18:30-19:00 Immunotherapy in earlier stages A. Marabelle - TBC

Plenary lecture19:00-19:45 Precision Medicine in Cancer C. Le Tourneau (FR)

Saturday, December 1st, 2018 SESSION 6: Biomarkers for Immunotherapy09:30-10:00 Advances on biomarkers for immunotherapy beyond PD-L1 expression TBD 10:00-10:30 Activatedintegrinsrevealfunctionalantigen-specificTcells C. Gouttefangeas (DE) 10:30-11:00 Using genomic signatures as predictive marker for immunotherapy C. Denkert - TBC 11:00-11:30 Tumor-associated and non tumor associated microbiota TBA

11:30-11:45 Co f fee b reak

Plenary lecture11:45-12:30 Immune contexture as a prognostic biomarker H. W. Fridman (FR)

12:30-13:45 Short oral presentations-clinical 13:45-15:00 Lunch b reak

SESSION 7: Immunotherapy (II)15:00-15:30 Adoptive Cell therapy in solid tumors T.H. Borch (DK) 15:30-16:00 Therapeuticadvancesofimmunotherapyinthefieldof mesenchymal tumors D. Heymann (UK) 16:00-16:30 Immunotherapy in GU Cancer N. Pistamaltzian (GR) 16:30-17:00 Immunotherapy in Blood Cancers G. Vassilopoulos (GR)

17:00-17:30 Co f fee b reak

Plenary lecture17:30-18:15 Intratumoral heterogeneity detected via next generation sequencing of T cell receptors R. Offringa (GE)

SESSION 8: Immunotherapy (III)18:15-18:45 Current status of immunotherapy in head and neck cancer A. Argiris (GR) 18:45-19:15 Whatisnewinimmunotherapyformelanoma M. Neagu (RO) 19:15-19:45 Overcoming primary and acquired resistance in immune checkpoint inhibitors C. N. Baxevanis (GR) 19:45-20:15 Management of toxicities A. Koumarianou (GR)

20:15-20:45 Awards - Closing remarks

CALL FOR ABSTRACTS 2018TheOrganizingandScientificCommitteesofthe4th Symposium on Advances in Cancer Immunology and Immunotherapyinvitesubmissionofscientificabstractsforshortoralandposterpresentations.

AbstractsmustbesubmittedinEnglishthroughtheSymposiumofficialwebsite: www.hellenic-immunooncology.gr

Abstractswillbeselectedonscientificmerit.Abstractsubmissionstarts on August 6th, 2018

PleasesubmityourabstractviatherelevantformontheSymposiumWebsite. Submissions by fax or post will NOT be accepted.

Abstract submission will close at 24:00 hours Central European Time (CET) on Sunday, October 28th, 2018.

NotificationofacceptancewillbemadebyNovember 12th, 2018.

S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y S y m p o s i u m o n A d v a n c e s i n C a n c e r I m m u n o l o g y a n d I m m u n o t h e ra p y

06

NOTESNOTES

General InformationO r g a n i z e d b y Hellenic Society of Immuno-Oncology (HeSIO) G. Theologou 5, Τ.Κ.11474,Athens,Greece www.hellenic-immunooncology.gr

D a t e s November 29th - December 1st. 2018

W e b s i t e : http://hellenic-immunooncology.gr

S y m p o s i u m V e n u e Royal Olympic Hotel, Athens 28-34,AthanasiouDiakouStr.,11743,Athens,GREECE Tel.:+3021092.88.400 Fax:+3021092.33.317 E-mail: info@royalolympic.com

P r i c e p e r D e l e g a t e Registration Fee Undergraduate students and postgraduate students 0€ PhD students 0€ Post-docs and MD 200€

C e r t i f i c a t e o f A t t e n d a n c e Based on the latest circular of the National Drug Organization the Symposium is required to use an attendance trackingsystem.Allregisteredparticipantswillreceivenamebadges,whichtheyarekindlyrequestedtowearatall times. Each badge will have a barcode for monitoring the hours of attendance. By the end of the symposium a certificatewillbegiventothosewhohaveattendedatleast60%ofthetotalhoursoftheScientificProgram.

O f f i c i a l L a n g u a g e EnglishistheofficiallanguageoftheSymposium.

S y m p o s i u m S e c r e t a r i a t

Sc ien t i f i c Ι Cu l tura l Events and Pub l i ca t ions T+302107240039F+302107240139E info@scep.gr www.scep.gr